Once again, finerenone proved to reduce the risk of cardiovascular and kidney outcomes in diabetics on maximal dose ACE inhibitor or ARB, with lower rates of hyperkalemia compared to placebo across stages of kidney disease (70). This evidence concerns the gene ACE and kidney disorder.